The Cancer Drug Price Cut Stops Where the Patents Begin
By Arunima Rajan
The NPPA margin cap lowers prices on off-patent cancer medicines but leaves the newest therapies untouched. Arun Asaithambi, founder and CEO of Katamaran Industries, on what hospitals should expect and what would make the next generation of drugs affordable.
Tell us briefly about your background, including founding Lantern Pharma, and what led you to start Katamaran. What is the company working on today?
Arun Asaithambi, Founder and CEO, Katamaran Industries
I founded Lantern Pharma in 2013, part of the first wave of companies applying AI to cancer drug development, and was its founding CEO; the company listed on Nasdaq in 2020. Before that, I completed my PhD and postdoctoral research in biotechnology at Iowa State University in the US.
Over more than a decade of building AI for cancer drug development, the lesson that stayed with me is that these models are only as good as their data. Across the industry, most data on how cancers respond to drugs comes from cell lines and animals, so models learn their biology rather than that of human tumours. That is a big reason why so many drugs that look promising in the lab fail in patients. I started Katamaran to generate the missing data: drug responses measured in real human tumours.
Katamaran Industries is a Bengaluru-based biotech company working in oncology drug discovery. We test drugs on thin slices of fresh tumour tissue removed during surgery, with patient consent and ethics approval. The slices keep much of the tumour's original structure, including its supporting tissue and immune cells, and we pair each response with genomic, transcriptomic and pathology data from the same tumour.
These data train our AI platform, KAPA, to predict which tumours respond to which drugs, and we use it to test candidates from our own discovery work before taking them forward. We presented our first dataset at ESMO 2026. The larger objective is to bring human tumour biology into the earliest stages of drug discovery, beyond what computer-based predictions alone can tell us.
From 9 November, the NPPA margin cap cut prices on hundreds of cancer drug brands, but patented single-brand therapies may see little or no reduction. Will this change what hospitals actually pay for the newest cancer treatments, or mainly for older generics and biosimilars?
I see this as a welcome step. The order caps trade margins on 137 non-scheduled anti-cancer drugs, which has reportedly brought down the MRP of more than 500 brands from 9 November. Patented medicines are excluded, so the newest single-brand therapies are unlikely to see much change. The biggest effect will be on off-patent drugs, generics and biosimilars.
The extent of the reduction will vary with the existing pricing structure of each medicine and the trade margins across its distribution network. It is important to recognise that regulating trade margins is different from reducing the manufacturer's selling price. This measure addresses the former and does not necessarily alter the latter.
For hospitals, this could mean lower procurement costs for the medicines covered, provided the revised prices are implemented across the distribution chain. It would be premature to expect substantial reductions across newer cancer treatments. Patent protection, manufacturing costs, competition and the availability of therapeutic alternatives will continue to shape the price of innovative medicines.
For patented medicines, the manufacturer's price itself remains the main affordability challenge, which is why margin regulation alone cannot address every aspect of cancer drug pricing. Sustained progress will depend on a broader approach that combines appropriate price regulation with greater competition, stronger domestic manufacturing and continued investment in drug discovery.
Hospitals have relied on pharmacy margins to support oncology services. If those margins shrink, how do you expect hospitals to respond, and what is the risk that costs simply shift to administration, consumables or package rates?
There is a distinction between reducing excessive trade margins and ensuring that hospitals remain financially sustainable. Both matter. Oncology services require investment in specialised infrastructure, trained personnel, diagnostics, treatment delivery and patient support, and those costs do not disappear when medicine prices come down.
I don't run a hospital, so I would be careful about speaking for them. But pharmacy income often helps fund oncology services that are poorly reimbursed on their own, such as day-care chemotherapy, oncology pharmacists, tumour boards and patient counselling. If margins shrink, the sustainable answer is to price those services transparently rather than recover the money through drug margins.
I would not assume that hospitals will automatically shift the reduction into other parts of a treatment package. That will depend on their procurement arrangements, operating costs and pricing practices. Transparency matters most during this transition: patients should be able to understand how medicine costs, hospital charges and other components of their bills are calculated.
An Indian study of 12,148 patients found that medicines make up 45% of hospitalisation-related out-of-pocket spending on cancer. From your experience in drug development, what drives the high cost of newer cancer drugs, and what would genuinely bring it down?
The cost of developing a new cancer drug goes well beyond the price of its ingredients or manufacturing. It reflects years of research, development, testing and clinical evaluation, often involving substantial investment with no guarantee of success. Many promising candidates fail along the way, and the cost of those unsuccessful programmes is part of the economics of drug development.
It is also important to distinguish between the average cost of cancer treatment in India and the cost of accessing newer therapies. The same study's estimate of around ₹3.3 lakh in annual out-of-pocket spending is an all-cancer average. It does not capture what a patient may have to spend when a newer targeted therapy or immunotherapy is indicated.
Pembrolizumab, for example, has been reported to cost ₹1.5–2.2 lakh per 100 mg vial in India. Even under the patient-access programme, patients reportedly have to buy around ₹10 lakh worth of the drug before free vials apply. This illustrates the affordability gap between conventional cancer treatment and newer innovative medicines.
Newer cancer therapies often require complex research, specialised manufacturing and extensive clinical development. Patent protection and limited competition further influence pricing once they reach the market.
Addressing this requires us to look at the entire drug development process rather than only the final selling price. We need better ways to identify promising drug candidates, understand their behaviour in human biology and detect likely failures much earlier. This is where combining computational tools with human-relevant disease models can make a meaningful difference. At Katamaran, our work with patient-derived tumour tissue focuses on measuring actual tumour responses during early-stage drug discovery.
India also needs stronger research infrastructure, closer collaboration between academic institutions, biotechnology companies and hospitals, and greater investment in original drug discovery. Improving access to existing medicines is essential, but building the country's ability to discover the next generation of cancer treatments more efficiently is equally important.
This is the larger problem we are working on at Katamaran: making the discovery of new cancer drugs more cost-efficient by combining computational research with human-relevant disease models grounded in actual tumour responses. We are not yet at the stage of delivering treatments to patients, but we believe that making drug discovery more efficient is an important part of making future cancer therapies more affordable.
Many patients receive drugs that don't work for their particular tumour. How high a cost is ineffective treatment for hospitals, insurers and schemes such as PM-JAY, and what can hospitals do today to reduce it?
The biggest cost of an ineffective treatment is often time. A patient can lose weeks or months on a drug that was never going to work, while the disease progresses and better options narrow. The financial cost extends well beyond the medicine itself: consultations, diagnostic tests, hospital visits and supportive care can all be incurred without the intended benefit, alongside a considerable physical and emotional burden.
For hospitals, insurers and publicly funded schemes such as PM-JAY, ineffective treatment means significant resources spent without the expected clinical benefit. The impact varies with cancer type, stage at diagnosis, treatment regimen and payment arrangement, so it would be difficult to assign a single figure without more specific data. The burden is greatest when a patient receives an expensive targeted therapy or immunotherapy that does not work for them.
A key challenge is that tumours can behave differently even when they are classified as the same cancer type. In our own research, tumours of the same cancer type often respond very differently to the same drug in the lab. Understanding this biological variation is essential to improving treatment decisions over time.
Hospitals can act today: use molecular testing where guidelines support it, review complex cases in multidisciplinary tumour boards, track outcomes by regimen, and take part in well-designed research, including consented tissue studies. At the same time, studying drug responses in a research setting is not the same as having a validated test that can reliably guide treatment for an individual patient. Maintaining that distinction is essential as precision oncology advances.
The National Cancer Grid's pooled procurement has cut prices of some cancer medicines by a median of 82%. Should private hospitals buy together in the same way? What stops them, and what would it take?
The National Cancer Grid's pooled procurement initiative is a useful example of what collective purchasing power can achieve. When hospitals aggregate demand, they can negotiate better prices, standardise procurement terms and potentially improve access to medicines that would otherwise be expensive.
I believe private hospitals could explore similar models, particularly for medicines with predictable demand and established supply chains. It would need coordination between institutions and clarity on procurement volumes, quality standards, pricing and supply commitments.
There are practical challenges. Hospitals may have different formularies, patient profiles, procurement systems and vendor relationships. They may also worry about losing flexibility in sourcing and about uninterrupted supply. A pooled model would need to account for these differences rather than assume that every hospital can follow the same structure.
The larger lesson is that affordability does not have to come from price regulation alone. Better procurement practices, stronger competition and collaboration between healthcare institutions can also make a meaningful difference.
Can drugs discovered and developed in India reach Indian patients at lower prices than imported therapies? What role can hospitals play, whether through research partnerships, clinical trials or data, and what do they gain?
Yes, I believe India has the scientific talent and healthcare ecosystem to play a larger role in original drug discovery. But developing a drug in India does not automatically make it cheaper. The cost depends on the research process, development timelines, manufacturing, clinical trials, the regulatory pathway and eventual market competition.
Where India can make a difference is by building stronger capabilities across the discovery and development pipeline. We have a large and diverse patient population, a growing biotechnology sector and established pharmaceutical manufacturing. These are important strengths, but they need sustained investment in research, infrastructure and collaboration.
India's indigenous CAR-T therapy, NexCAR19, is an encouraging example. Reported to cost around one-tenth of comparable global CAR-T products, it shows how developing therapies within India can lower the cost barriers of advanced treatments. Every therapy has its own development and manufacturing economics, but it is a clear example of why India needs to invest in original drug discovery rather than rely mainly on imported innovation.
Hospitals can be important partners in this process, through ethical research collaborations, clinical trial infrastructure, scientific expertise and high-quality clinical data, with appropriate patient consent, privacy safeguards and regulatory oversight.
Such partnerships help hospitals take part in developing new treatments, strengthen their research capabilities and contribute to evidence generation. For biotech companies, they provide the clinical expertise and research environments that are essential for translating early scientific work into potential therapies.
Hospitals are increasingly approached by AI and biotech startups promising cheaper, better cancer care. Having built and invested in such companies, what should a hospital CEO ask before partnering with one, and what are the red flags?
Hospital leaders should start with a simple question: what exactly is the company trying to solve, and what evidence does it have that its approach works?
In healthcare, an impressive technology demonstration does not necessarily translate into clinical value. Hospitals need to know where the solution stands: still at the research stage, tested in a laboratory, or clinically validated. They should also examine the quality of the data, the methodology, the limitations of the technology and whether its findings have been independently evaluated.
There are practical considerations too, particularly with biotech or AI-led research companies. Hospitals should be clear about what is expected of them, how patient data and biological samples will be used and protected, what ethical and regulatory approvals are required, and who will own the research findings and intellectual property.
Hospital leaders should be cautious of companies that promise guaranteed outcomes, suggest that their technology can replace established clinical judgement, or cannot explain how their results were validated. Claims of lower costs or better outcomes should be supported by evidence rather than projections.
A good partnership begins with a clearly defined problem and realistic expectations. Hospitals should work with companies that are transparent about their capabilities, open about their limitations and willing to prove the value of their technology through rigorous research. In healthcare, clinical evidence and patient safety must remain the basis of every partnership.
Got a story that Healthcare Executive should dig into? Shoot it over to arunima.rajan@hosmac.com—no PR fluff, just solid leads.